Truscreen Group Ltd. · NZX:TRU
Truscreen — Shareholder Meeting (September 2026)
43 slides from Truscreen's shareholder meeting presentation, Sep 1, 2026
Slide 1: Annual Shareholders Meeting
For personal use only Annual Shareholders Meeting 1 September 2026
Slide 2: For personal use only
• Who is TruScreen For personal use only • The TruScreen Technology • The Global Cervical Cancer Screening Market • TruScreen Sales and Growth Strategy
Slide 3: Who is TruScreen
For personal use only Who is TruScreen Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution
Slide 4: TruScreen at a glance
TruScreen Group Ltd is a revenue generating Life Science company with a unique, AI-enabled real-time cervical cancer screening device. For personal use only FY26 annual sales exceeded NZ$ 2.4m 42% YOY growth. 4
Slide 5: Key financials FY26
Device installations and SUS Sales KEY FINANCIALS FY 23 FY 24 FY25 FY26 NZ$ (m) Actual Actual Actual Actual Sales 1.66 2.1 1.7 2.4 Total Revenue 2.2 2.6 2.1 2.8 For personal use only COGS 1.3 1.4 1.2 1.7 R&D 0.9 0.9 0.8 0.9 EBITDA -2.4 -2.0 -2.2 -2.2 Write off of Non-Current Assets -0.05 - - - Amort
Slide 6: Share Price History
Share Price History TRU.NZ For personal use only TruScreen Group Ltd is dual listed Market Capitalisation at 24 August 2026: Shares on Issue: on the Australian (ASX) and New NZD $15.7m 1,047,718,877 Zealand (NZX) stock exchanges, with a common ticker code of TRU. 6
Slide 7: Major Shareholders
Major Shareholders Shareholder Shares % New Zealand Depository Nominee 135,078,919 12.9% VEN Capital Pty Ltd 83,545,906 8.0% Ryan Peter Parkin 38,734,331 3.7% New Zealand Central Securities 38,075,089 3.6% For personal use only Bhagwanji Bhula Rama 34,849,999 3.3% HSBC Custody Nominees 30,385,427 2.
Slide 8: The TruScreen Journey
The TruScreen Journey Building the Fundamentals 2014 - 2020 Building for the Future 2020-2024 2025 & Beyond For personal use only 2017 Dec 2018 Oct 2019 May 2022 2025 CFDA (NMPA) 523% sales Recognition by Managing COVID-19 challenges China Growth continues approval for second growth in H1 World Heal
Slide 9: TruScreen's Development Investment
TruScreen’s Development Investment 1987 – 2013 2014 - 2026 For personal use only • Algorithm Development • Algorithm Improvement ~A$75M* • Device Development ~NZ$25 • Device Miniaturisation • Single Use Sensor M • Single Use Sensor Process (NZ$87m) Development Improvement • Clinical Trials • Clinica
Slide 10: NZ$5M capital raised June 2026
NZ$ 5M capital raised June 2026 Placement Options Rights Offer A placement to institutional and other Shares issued under the A one (1) for five (5) pro-rata select investors in New Zealand and Placement carried renounceable rights issue to Australia to raise up to NZ$1m attaching options with an ra
Slide 11: The TruScreen Technology
For personal use only The TruScreen Technology
Slide 12: How The TruScreen Device works
How The TruScreen Device works A pen-like wand covered by a disposable Single Handheld device (HHD) Use Sensor (SUS) is used to gently touch multiple 1 spots on the cervix. The TruScreen device sends and picks up low level electrical and optical signals For personal use only Single Use Sensor (SUS)
Slide 13: Instant results, no laboratories needed
Instant results, no laboratories needed. TruScreen provides an instant result during the patient visit ensuring patients are not lost to follow up whilst waiting for a screening result - often weeks or months. For personal use only This enables immediate counselling and clinical action. No laborator
Slide 14: TruScreen Regulatory Approvals
TruScreen Regulatory Approvals International Quality Recognized by International Approvals: Accreditation: • CE Mark, European Union • ISO 13485 • World Health Organisation (WHO) For personal use only • NMPA, China • UNITAID • IEC 60601-1 • TGA, Australia • Clinton Health Access Initiative • MHRA, U
Slide 15: Extensive body of clinical evidence
Extensive body of clinical evidence Over 40,000 women in clinical trials to date*** For personal use only Year Country Investigator N Year Country Investigator N 2002 China Dr Huang Yi 683 2019 China Dr. Baojin Wang 315 2002 China Dr Wang Ziyao 301 2019 China Dr. Wei Zhang 1030 2003 UK/Aus Prof A. S
Slide 16: COGA Trial
COGA Trial (n= 14,982, 2018-2021) 4 • COGA multicentre trial (64 hospitals, 9 provinces), represents the world’s largest opto-electronic cervical screening study • TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV • TruScreen was determined to be a simple, effective and rapid rea
Slide 17: The Global Cervical Cancer Screening Market
For personal use only The Global Cervical Cancer Screening Market
Slide 18: Cervical Cancer Is A Global Public Health Issue
Cervical Cancer Is A Global Public Health Issue† Fourth most common cancer in For personal use only Every 2 minutes, a Most diagnoses women worldwide, but preventable - in occur at working age women dies from fact only one of a handful of cancers cervical cancer. (35-44) that we understand fully. Ar
Slide 19: The Size of the Cervical Cancer Screening Market
The Size of the Cervical Cancer Screening Market • The global cervical cancer screening market was valued at ~US$ 7.9 billion in 2024 - projected to reach US$ 14.5 billion by 2033, an annual growth rate of 5.8% (CAGR).1 2024 2033 • Cervical cancer cases globally rose 16% from 570,000 (2018) to 662,3
Slide 20: WHO & Countries are committed to eliminating Cervical Cancer
WHO & 194 Countries are committed to eliminating Cervical Cancer • In 2020 The World Health Organisation (WHO) and 194 member countries agreed on a strategy to eliminate cervical cancer this century For personal use only 90% 70% 90% 90% HPV Vaccination 70% of women screened using a high- 90% of wome
Slide 21: Market Potential
For personal use only Market Potential 21
Slide 22: The Problem That TruScreen Solves
The Problem That TruScreen Solves. HIC’s vs LMIC’s: Lab based platforms and VIA are struggling to meet the screening needs of LMIC’s, faced with 94% of cervical cancer deaths, limited access to laboratory resources and over reliance on inaccurate VIA programs. For personal use only High-Income Count
Slide 23: Why TruScreen?
Why TruScreen? TruScreen Liquid Based Cytology (LBC) HPV DNA Real time results For personal use only Low infrastructure costs Strong clinical results Objective results Low training threshold Portable No cell or tissue samples taken 23
Slide 24: Complete patient data safety and privacy
Complete patient data safety and privacy – a legal and regulatory must. • TruScreen’s algorithm is contained within the device, not the Cloud. For personal use only • TruScreen’s patient data is encrypted and stored within the device. • TruScreen does not send data to the Cloud. • TruScreen will con
Slide 25: TruScreen Sales & Growth Strategy
For personal use only TruScreen Sales & Growth Strategy
Slide 26: Recurring Revenue Model
Recurring Revenue Model • TruScreen manufactures two devices – o one made in China for use in China, where locally manufactured products have For personal use only preferential market access o one made in Australia for other markets • For each patient screened with the TruScreen device a new disposa
Slide 27: TruScreen Sales Strategy
TruScreen Sales Strategy • Whilst many other medical technology companies seek to commercialize their devices in developed countries, TruScreen focuses on Low and Middle Income Countries (LMICs) such as China, Mexico, Vietnam, India, Indonesia and Zimbabwe. For personal use only • Working with globa
Slide 28: Global presence
Global presence Registration and sales activity in Russia, Kazakhstan, Kyrgyzstan, Armenia and Belarus Uzbekistan product registration completed. Validation trial of TruScreen for a national cervical cancer screening program Inclusion in Chinese Obstetricians and commenced. Gynecologists Association
Slide 29: For personal use only
NZ $2.4M 232 1.1m+ 20 For personal use only FY26E Devices operational Women Active Revenue worldwide Screened Countries • TruScreen operates in a favourable macro environment defined by the WHO 2030 90-70-90 cervical cancer elimination strategy • Unmet screening demand in low- and middle-income coun
Slide 30: FY25 Actual vs FY26 Actual
FY25 ACTUAL FY26 ACTUAL NZ$1.7m NZ$2.4m For personal use only 30
Slide 31: The Game Changers - NGOs and Population Screening Programs
The Game Changers - NGO’s and Population Screening Programs For personal use only 1 The timeline compression of WHO’s 90-70-90 milestones to December 2030 - sense of urgency UNITAID and global NGOs funding 2 from late 2026 to drive cervical cancer screening 31
Slide 32: Transformational opportunities through UNITAID Call for Proposals
Transformational opportunities have recently arisen through global funder UNITAID's Call for Proposals: Accelerating Cervical Cancer Elimination through Secondary Prevention in Low and Middle Income Countries. For personal use only Three grant applications have been made to UNITAID to screen an addi
Slide 33: Unitaid: Proposal
Unitaid: Proposal 1 Accelerating Cervical Cancer Elimination through AI-Enabled Point-of-Care Screening in Sub-Saharan Africa For personal use only Partners: 1. National AIDS Council (NAC), Zimbabwe - Country implementation lead (Zimbabwe) 2. PATH - Global technical partner (Program for Appropriate
Slide 34: Unitaid: Proposal
Unitaid: Proposal 2 Screen-and-Treat Africa: Accelerating Cervical Cancer Elimination through Dual HPV-TruScreen Screening and Same-Day Treatment in Sub-Saharan Africa For personal use only Partners: 1. National AIDS Council (NAC), Zimbabwe - Country implementation lead (Zimbabwe) 2. PATH - Global t
Slide 35: Unitaid: Proposal
Unitaid: Proposal 3 Accelerating Cervical Cancer Elimination through AI-Enabled Real-Time Screening in the Asia-Pacific and Latin America For personal use only Partners: 1. PATH (Program for Appropriate Technology in Health ) 2. Ho Chi Minh City Public Health Association 3. Gordon Health Services Vi
Slide 36: Bill and Melinda Gates Foundation Proposal
Bill and Melinda Gates Foundation Proposal Partners: 1. Nigeria’s Lagos State University Teaching Hospital (LASUTH) 2. Lagos State University College of Medicine (LASUCOM) 3. Dr. Ayokunle Moses Olumedji, Consultant Gynaecological Oncologist at LASUTH Country: For personal use only Nigeria Beginning
Slide 37: Clinton Health Access Initiative
Clinton Health Access Initiative Partners: 1. National AIDS Council (NAC), Zimbabwe - Country implementation lead (Zimbabwe) 2. PATH - Global technical partner (Program for Appropriate Technology in Health ) For personal use only 3. Solina Centre for International Development and Research (SCIDaR) -
Slide 38: Other National or NGO Programs
Other National or NGO Programs: Zimbabwe – Re Validated by Ministry of Health and NACAIDS • WLWHIV are 6x More likely to die from Cervical Cancer • Next 10,000 Women program to commence in September • Validation recommends TS for inclusion in Zimbabwe’s National Screening Program For personal use on
Slide 39: DaltonBio Strategic Alliance
DaltonBio Strategic Alliance • FY25 - Memorandum of Understanding signed with Dalton Biosciences (DaltonBio) • FY26 - TruScreen and Dalton Bio sign Distribution Agreement for HPV For personal use only products in India 1. TruScreen to be appointed a global distributor of DaltonBio HPV related IVD pr
Slide 40: Thank you
Thank you. For personal use only Tony Ho Marty Dillon Non-Executive Chairman CEO E – tonyho@truscreen.com E – martindillon@truscreen.com TruScreen Suite 3.03 18 Orion Rd Lane Cove West NSW 2066 Australia www.truscreen.com
Slide 41: Disclaimer and important notice
Disclaimer and important notice This presentation has been prepared by TruScreen Group Limited (TRU). Information of a general nature: This presentation contains summary information about TRU and its activities which is current as at the date of this presentation. The information in this presentatio
Slide 42: Disclaimer and important notice (Continued)
Disclaimer and important notice (Continued) Future performance (continued): The forward-looking statements are based on information available to TRU as at the date of this presentation. Except as required by law or regulation (including the NZX and ASX Listing Rules) TRU undertakes no obligation to
Slide 43: Disclaimer and important notice (continued)
Disclaimer and important notice (continued) Distribution of presentation: This presentation (including an electronic copy) must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or prohibited by law or would constitute a breach by TRU of an
TruScreen Group — Shareholder Meeting (September 2026) on 6ix